NSE ScannerComparison · NSE · data 2026-11-01
Marksans Pharma Limited vs NATCO Pharma Limited
In plain words
Size: NATCO Pharma Limited is about 1.1 times the market value of Marksans Pharma Limited.
Valuation (P/E): Marksans Pharma Limited 26.9 vs NATCO Pharma Limited 12.4.
Return on equity: NATCO Pharma Limited 16.9% vs Marksans Pharma Limited 15.2%.
Profit growth over 3 years: NATCO Pharma Limited 25.6% a year vs Marksans Pharma Limited 16.2% a year.
Debt to equity: Marksans Pharma Limited 0.11 vs NATCO Pharma Limited 0.08.
Differences in the numbers, not a recommendation of either stock.
Side by side
| MARKSANS | NATCOPHARM | |
|---|---|---|
| Price | ₹306.2 | ₹782.4 |
| Market cap | ₹13,896 cr | ₹15,350 cr |
| P/E | 26.9 | 12.4 |
| P/B | — | — |
| ROE | 15.2% | 16.9% |
| ROCE | 16.3% | 15.6% |
| Debt / equity | 0.11 | 0.08 |
| Operating margin | 19.3% | 24.6% |
| Dividend yield | 0.29% | 0.57% |
| Sales growth, 3 years (yearly) | 16.7% | 14.5% |
| Profit growth, 3 years (yearly) | 16.2% | 25.6% |
| 1-year return | 66.7% | -4.8% |
| Revenue, last 12 months | ₹3,172 cr | ₹3,485 cr |
| Net profit, last 12 months | ₹517 cr | ₹1,144 cr |
| Latest quarter | Jun 2026 | Jun 2026 |
| Quarter net profit | ₹157 cr | ₹207 cr |
| Quarter profit vs a year earlier | +169.5% | -57.0% |
| Promoter holding | 43.87% | 49.39% |
| Health check | Strong (8.5/10) | Strong (6.8/10) |
Common questions
Which has a higher P/E, Marksans Pharma Limited or NATCO Pharma Limited?
Marksans Pharma Limited trades at the higher P/E (26.9 against 12.4). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
NATCO Pharma Limited (16.9% against 15.2%).
Which carries more debt?
Marksans Pharma Limited has the higher debt-to-equity ratio (0.11 against 0.08).